Medical cannabis, especially in higher THC doses, has been approved for use in the United Kingdom and Germany plus 24 other European countries for conditions including but not limited to chronic pain, Spinal cord treatment, Anxiety, HIV/AIDS Appitite loss, Multiple Sclerosis, Crohn’s disease, PTSD, Chemotherapy side effects, Glaucoma, Anorexia, Lennox-Gastaut syndrome, Alzheimer’s, Dravet syndrome, Tourette’s syndrome, Intractable spasticity and Cachexia.

Hellenic was awarded its licence from the Greek government in 2019 for a total of 40,000 square meters of active cultivation area within our facility, with no limitations on the THC content of the cultivars grown, the overall volume of production or total export quantities of flowers per annum. This is one of the largest licences of its kind issued in Europe due to the size and scale of the facility and the high regulatory standards under which Hellenic Dynamics operates.

Hellenic Dynamics has an experienced management team with significant medial cannabis cultivation and business development experience. This skillset is underpinned by a number of high profile partnerships and collaboration agreements that cover all aspects of the Company’s marketing, sales, security and existing legislative and legal frameworks both domestically and for target European sales territories.